A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis

Area of Science:

• Biomedical Engineering
• Cancer Research
• Analytical Chemistry

Background:

• Immunohistochemistry (IHC) is crucial for biomarker-driven cancer therapy.
• Standardization and quality assurance in IHC are challenging due to complex testing and subjective validation.
• Current IHC quality control methods lack objectivity and efficiency.

Purpose of the Study:

• To develop a microfluidic system for standardizing immunohistochemistry (IHC) staining.
• To create a quantitative quality assurance testing method for IHC.
• To screen biomarker staining conditions efficiently and objectively.

Main Methods:

• Development of a microfluidic linearly graded antibody (Ab)-staining device.
• Creation of a reference cell microarray for IHC validation.
• Characterization of Ab staining intensity using three different HER2 antibodies.
• Validation of antibody quality using breast cancer patient tissues.

Main Results:

• The microfluidic system demonstrated effective standardization of IHC staining.
• Quantitative assessment of antibody staining intensity was achieved.
• The system successfully validated the quality of different HER2 antibodies.
• The method proved efficient for screening staining conditions.

Conclusions:

• The developed microfluidic immunostaining system offers a powerful tool for IHC standardization.
• This approach provides a quantitative method for quality assurance in IHC testing.
• The system enhances the reliability of biomarker-driven cancer therapy through improved IHC quality.